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Abstract: Lung tissue from COPD patients displays oxidative DNA damage. The present 
study determined whether oxidative DNA damage was randomly distributed or whether it 
was localized in specific sequences in either the nuclear or mitochondrial genomes. The DNA 
damage-specific histone, gamma-H2AX, was detected immunohistochemically in alveolar wall 
cells in lung tissue from COPD patients but not control subjects. A PCR-based method was 
used to search for oxidized purine base products in selected 200 bp sequences in promoters 
and coding regions of the VEGF, TGF-β1, HO-1, Egr1, and β-actin genes while quantitative 
Southern blot analysis was used to detect oxidative damage to the mitochondrial genome in lung 
tissue from control subjects and COPD patients. Among the nuclear genes examined, oxida-
tive damage was detected in only 1 sequence in lung tissue from COPD patients: the hypoxic 
response element (HRE) of the VEGF promoter. The content of VEGF mRNA also was reduced 
in COPD lung tissue. Mitochondrial DNA content was unaltered in COPD lung tissue, but there 
was a substantial increase in mitochondrial DNA strand breaks and/or abasic sites. These find-
ings show that oxidative DNA damage in COPD lungs is prominent in the HRE of the VEGF 
promoter and in the mitochondrial genome and raise the intriguing possibility that genome and 
sequence-specific oxidative DNA damage could contribute to transcriptional dysregulation and 
cell fate decisions in COPD.
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Introduction
Multiple lines of evidence show that COPD is inextricably linked to oxidant stress.1–3 
Sources of oxidants in smoking-related COPD are complex, but probably involve potent 
oxidants in cigarette smoke as well as oxidants elaborated by infiltrating inflammatory 
cells and generated as a consequence of cellular signaling. The oxidants so produced 
appear to target molecules and cellular pathways involved in cell death and lung 
inflammation. Recent studies have demonstrated in lung and peripheral blood cells 
from patients with tobacco smoking-related COPD that nucleic acid pools, including 
guanine incorporated into RNA and DNA, are oxidatively damaged.4–7 Accumulation 
of oxidative damage to nucleic acids by cigarette smoke may lead to an increased 
risk of cancers and lung aging;8,9 in fact, COPD lungs have increased expression of 
  markers of cellular senescence, which may correlate with decreased lung repair, further 
increasing tissue damage that characterizes the progressive and irreversible nature of 
lung destruction in COPD.10,11
Traditional concepts hold that oxidative DNA damage is largely random and 
it triggers activation of the base excision DNA repair (BER) pathway aimed at the International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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removal of the damage to minimize its potentially mutagenic 
consequences. However, emerging evidence suggests that 
under some circumstances oxidative DNA damage is not 
random; damage can be localized to, or more prominent in, 
either nuclear or mitochondrial (mt) genomes. In this con-
text, while mtDNA appears to be considerably more prone 
to damage evoked by exogenously applied oxidants than the 
nuclear genome,12–14 specific promoter sequences in particular 
nuclear genes seem to be targeted for oxidative base damage 
by stimuli inducing their transcriptional activation.15–19
These considerations led us to hypothesize that   oxidative 
DNA damage in lung cells from COPD might be   nonrandomly 
distributed between mitochondrial and nuclear genomes, and in 
the latter case, could be targeted to specific sequences in spe-
cific genes. Because the site of oxidative DNA damage could 
have important implications for cellular responses underlying 
COPD pathogenesis, we used complementary strategies to 
identify lung cell populations harboring DNA damage and then 
searched for oxidative DNA damage in the mitochondrial and 
nuclear genomes, including specific sequences of genes linked 
to development of COPD. Our data indicate that severe COPD 
is indeed linked to oxidative DNA damage, characterized by 
prominence to the mitochondrial genome and to a function-
ally relevant sequence of the VEGF promoter, a gene whose 
dysregulation has been incriminated in COPD.20–23
Methods
Lung tissue procurement
Control and lung tissue from patients with GOLD 4 COPD was 
obtained from the Lung, and Blood Lung Tissue   Repository 
Consortium, provided relevant clinical data. The study was 
approved by the Johns Hopkins University and University of 
Colorado Institutional Review Boards. Control lung tissue 
was histologically normal and derived from patients with no 
evidence of respiratory dysfunction or COPD.
Immunohistochemical localization  
of the DNA damage-specific histone,  
gamma-h2AX
Paraffin-embedded, formalin-fixed lung tissue specimens 
were stained immunohistochemically for assessment of 
the disposition of gamma-H2AX, a DNA damage-specific 
  histone.24 We used the mouse monoclonal anti-gamma-
H2AX (phosphorylated S319) (Abcam, ab 2251, at 1 mg/mL) 
and as negative control, anti-gamma H2AX incubated with 
neutralizing peptide (Abcam, ab5649, Cambridge, MA) at 
0.1 peptide:1 antibody molar ratios, as recommended by 
the manufacturer. Antigen retrieval consisted of incubation 
with 0.25 mM EDTA at 95°C, followed by incubation in RT 
(real time) for 20 minutes. Nonspecific binding sites were 
blocked with 10% normal goat serum in Superblock (ScyTek 
Laboratories, Logan, UT). The detection of   antibody   binding 
relied on incubation with a polyclonal goat   anti-mouse 
antibody conjugated to Alexa Fluor 594 (Invitrogen, 
A11005, 2 mg/mL, Carlsbad, CA) with nuclei stained with 
 4 ′,6-diamidino-2-phenylindole (DAPI).
Methods for immunohistochemical analyses have 
been described previously.25 Quantification of expression 
  (normalized by total nuclear profiles) was performed in digitally 
acquired images (10 fields/slide) using MetaMorph® Imaging 
Software (Molecular Devices, Inc., Sunnyvale, CA).
DnA isolation and DnA damage 
assessment
Genomic DNA was isolated from lung tissue specimens using 
the silica-gel-membrane based DNeasy Tissue Kit (Qiagen, 
Valencia, CA) with the following modifications implemented 
to prevent artifactual oxidation: all buffers were purged 
with nitrogen, and after elution of purified DNA, 1 mM 
  dithiothreitol was added prior to storage at −80°C.
A previously reported polymerase chain reaction (PCR)-
based assay was used to detect base modifications in short 
sequences of selected nuclear genes.19,26 We concentrated 
our analyses on specific DNA sequences in several genes 
previously reported to be dysregulated in COPD lung tissue, 
including the TGF-β1, heme oxygenase-1 (HO-1), Egr1, and 
VEGF genes.27–30 β-Actin was used as a “housekeeping” gene. 
The position of the sequences examined in each gene and 
primers used to amplify the sequences of interest are listed in 
Table 1. The basis of the assay is that treatment of DNA with 
formamidopyrimidine DNA glycosylase (Fpg: New England 
Biolabs, Beverly, MA) results in strand cleavage at sites of 
oxidized purines, thereby creating single strand breaks that 
block PCR amplification. Differences in PCR amplification 
between Fpg-treated and untreated DNA are thus a specific 
indicator of the presence of oxidative base damage. The Fpg 
cleavage reaction was performed by incubating 250 ng of 
genomic DNA with 8 units of Fpg in 1X NEBuffer 1 (10 mM 
Bis Tris Propane-HCl, 10 mM MgCl2, 1 mM DTT, pH 7.0) 
and 100 µg/mL bovine serum albumin in a volume of 50 µL. 
Incubations were carried out at 37°C for 16 hours. Fpg was 
then inactivated by heating at 60°C for 5 minutes. An aliquot 
containing 10 ng genomic DNA was then used for the PCR 
assay to detect Fpg-sensitive cleavage sites. Data are presented 
as the percentage intact DNA, calculated as the quotient of 
band intensities in Fpg-treated and untreated DNA × 100.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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A previously reported quantitative Southern blot technique 
was used to search for oxidative damage to the mitochondrial 
genome.13,17 After restriction with BamH1, samples were 
resuspended in a small volume of TE buffer and quantified 
using a Hoefer TKO mini-fluorometer and standards kit. 
Samples containing 5 to 10 µg DNA were heated, cooled at 
room temperature, and then incubated for 15 minutes with 
sodium hydroxide (0.1 N) to cleave DNA at sites of oxidative 
injury to the deoxyribose backbone. Samples were combined 
with 5 µL loading dye, loaded on to a 0.6% alkaline gel, and 
electrophoresed in an alkaline buffer. The DNA was then 
vacuum-transferred to Hybond N+ membrane (Amersham 
BioSciences, Little Chalfont, UK) and hybridized with 
32P-labeled probe overnight at 55°C. The mtDNA probe was 
generated using the human mtDNA sequence as the template 
with PCR primers indicated in Table 1. The 672-bp product 
hybridized to a 10.5 kb fragment of human mtDNA obtained 
after BamHI digestion. This sequence contained the com-
mon deletion region incriminated in various “mitochondrial 
diseases”.31 The membrane was then exposed to XAR-5 X-ray 
film (Eastman Kodak Co., Rochester, NY) and images were 
scanned with a GelLogic 1500 Imaging System (Eastman 
Kodak Co., Rochester, NY). Changes in the equilibrium lesion 
density were calculated as -ln of the quotient of hybridization 
intensities in treated and control bands.
slot blot analysis
Slot blot analysis was used to detect differences in mtDNA 
content between control and COPD lung tissue. DNA 
samples were digested with BamHI, precisely   quantified, 
adjusted to the same concentration with H2O, and treated 
with 0.3 M NaOH to denature the DNA. Samples of 
100, 50, and 20 ng were blotted onto a nylon membrane 
(Zeta-probe GT, Bio-Rad, Hercules, CA) using a slot blot 
apparatus (Hoefer, San Francisco, CA) hybridized with a 
mtDNA-specific probe, and then washed according to the 
manufacturer’s suggestions.
VEGF mRNA quantification
VEGF mRNA was determined in control and COPD lung 
tissue samples using quantitative RT-PCR, as previously 
described.19
statistical analysis
Data are presented as either the mean ± standard error 
or as scatter diagrams with mean values indicated by 
a   horizontal bar. Group-dependent differences were 
sought using   one-way ANOVAs in conjunction with 
Neumann–Kuels test when appropriate. Differences were 
considered significant when P , 0.05.
Results
Immunohistochemical detection  
of histone gamma-h2AX
We first documented that lungs of advanced COPD patients 
have expression of the DNA damage-associated histone, 
gamma-H2AX. While none of the controls had detectable 
gamma-H2AX immunoreactivity, we noted a wide varia-
tion of gamma-H2AX immunoreactivity in GOLD 4 COPD 
patients with elevated expression ranging from 0.5 to 240 
(normalized to the total number of DAPI positive cells). 
Representative photomicrographs are shown in Figure 1.
Oxidative base damage in nuclear genes
Table 2 displays the percentage of intact DNA for the 
indicated promoter and coding sequences in the TGF-β1, 
HO-1, Egr1, and β-actin genes in normal lung tissue and 
in lung tissue from patients GOLD 4 COPD. Statistical 
analyses of these data revealed that oxidative base dam-
age did not differ between groups in any sequence of the 
Figure  1  Expression  of  gamma-H2AX  detected  by  immunofluorescence  or 
immunohistochemistry  (bottom  panels)  of  normal  (upper  panels)  or  gOLD  2 
(middle  left)  or  gOLD  4  (middle  right)  representative  emphysematous  lungs. 
Note infrequent expression of gamma-H2AX in alveolar septal cells in normal lung 
(arrows). Positive (bottom left) and negative (peptide absorbed anti-gamma-h2AX 
antibody; bottom right) control staining of a lung adenocarcinoma detected using 
immunohistochemistry (bar = 10 µm).International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Table 2 Percentage of intact DNA in specific sequences of COPD-
related genes in control lung and in COPD lung tissue*
Promoter +  
response element
Promoter -  
response element
Coding  
region
A. TGF-β
  Control (5) 99.5 ± 8.2 92.7 ± 5.9 85.7 + 8.2
  COPD (10) 96.9 ± 2.0 93.1 ± 1.6 92.2 + 4.3
B. HO-1
  Control (9) 98.3 ± 3.5 96.8 ± 4.9 98.3 ± 2.9
  COPD (9) 81.6 ± 6.6 87.7 ± 6.6 85.3 ± 7.1
C. Egr1
  Control (6) 101 ± 7.5 86.6 ± 11.6 85.8 ± 4.4
  COPD (10) 77.4 ± 6.2 82.7 ± 6.2 92.0 ± 4.3
D. β-actin
  Control (6) 92.8 ± 5.9 87.6 ± 4.2 85.8 ± 4.4
  COPD (10) 89.1 ± 2.0 87.7 ± 4.2 92.0 ± 4.3
Note: *No significant differences in oxidative base damage were detected between 
lung tissues from control subjects and COPD patients for any of the sequences and 
genes examined.
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Figure  2  Fpg-sensitive  oxidative  DNA  damage  in  a  VEGF  promoter  sequence 
containing  the  hypoxic  response  element  (hre;  top)  but  not  in  a  functionally 
insignificant promoter (middle) or coding (bottom) sequences of the VEGF gene in 
lung tissue from control subjects and lung tissue from patients with gOLD 4 COPD. 
See Table 1 for relative positions of sequences examined. Each point represents lung 
tissue from an individual patient. 
Note: *Significantly decreased “% intact DnA” in comparison to control at P , 0.05.
  indicated genes, though there was a tendency for damage to 
be present in HRE-containing sequences of the HO-1 and 
Egr1 promoters. In marked contrast, the scatter diagrams 
displayed in   Figure 2 show that the frequency of oxidative 
DNA damage in the VEGF promoter sequence containing the 
HRE was significantly elevated in lung tissue from patients 
with GOLD 4 COPD in comparison with normal lung tissue. 
Oxidative base damage frequencies did not differ between the 
controls and patient groups for a VEGF promoter sequence 
not containing the HRE or for the   coding region of the VEGF 
gene. Thus, out of 15 sequences examined in 5 different 
nuclear genes, COPD-related   oxidative base damage was 
prominent in only 1, the HRE of the VEGF promoter.
Because oxidative damage to the VEGF HRE has the 
potential to impair VEGF mRNA expression, and since there 
is some discrepancy in the literature about VEGF mRNA 
expression in COPD patients,32,33 we used quantitative 
  RT-PCR to determine VEGF mRNA abundance in normal 
lung tissue and lung tissue from patients with GOLD 4 
COPD. As shown in Figure 3, we found that the abundance 
of VEGF mRNA was decreased in COPD lung tissue in 
comparison with normal lungs.
Mitochondrial DnA content  
and damage in COPD lung tissue
Initial experiments showed that there were no differences in 
mtDNA copy number normalized to nuclear DNA between 
control lung tissue and lung tissue from patients with GOLD 
4 COPD (Figure 4). Because mtDNA copy number does not 
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Figure 3 Quantitative rT-PCr analysis of VegF mrnA abundance in lung tissue 
from control patients (n = 5) and patients with gOLD 4 COPD (n = 10). 
Note: *Significantly decreased in comparison to control at P , 0.05.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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1 Patient #
mtDNA
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Figure 5 Top: quantitative Southern blot analysis of alkali-labile lesions in a 10.3 Kb 
mtDNA  sequence  obtained  from  lung  tissue  from  5  control  subjects  and  from 
4 patients with gOLD 4 COPD. note diminished hybridization intensities in lung 
tissue  samples  from  patients  with  COPD.  Bottom:  quantification  of  changes  in 
equilibrium lesion densities in a 10.3 Kb sequence of the mitochondrial genome in 
control and gOLD 4 COPD lung tissues normalized to total mtDnA abundance. 
horizontal bar indicates mean values. 
Note: *Significantly decreased “% intact DnA” in comparison to control at P , 0.05.
250 100 25 ug
1
2
3
4
5
6
7
8
9
10
CONTROL
COPD
m
t
D
N
A
/
u
g
 
n
D
N
A 5800
4800
3800
Control COPD
Figure 4 Top: slot blot for mtDnA in 6 control subjects (rows 1–6) and 4 (rows 
7–10) patients with gOLD 4 COPD. note lack of systematic differences in mtDnA 
hybridization intensities between controls and COPD lung tissue samples at the 
3 amounts of total DnA (250–25 µg) tested. Bottom: Quantification of mtDNA 
abundance in control and COPD lung tissues normalized to total DnA. horizontal 
bar indicates mean values.
differ between control and COPD lung samples, group-related 
differences in hybridization intensities for quantitative 
  Southern blot analyses of alkali-treated mtDNA reflect differ-
ences in the densities of strand breaks or apurinic/  apyrimidinic 
sites. As shown in Figure 5, lung tissue from patients with 
GOLD 4 COPD harbored   substantially increased   densities 
of strand breaks and apurinic/apyrimidinic sites in the mito-
chondrial genome than tissue from normal lungs.
Discussion
Compelling evidence demonstrates that the oxidant-rich 
environment associated with tobacco smoking leads to 
oxidative DNA damage and contributes to the pathogenesis 
of COPD.1–3 Potential sources of DNA-damaging reactive 
species include oxidants present in cigarette smoke, infiltra-
tion of reactive oxygen species (ROS)-generating inflamma-
tory cells and enzymes, and oxidants generated as second 
messengers in signaling. ROS-dependent DNA damage in 
COPD has been revealed by immunohistochemical analysis 
of the common DNA damage product, 8-oxoguanine, and 
by comet assays that detect strand breaks and base oxida-
tion products.4–7 These measurements have been applied to 
intact lung tissue, isolated lung cells, and circulating nucle-
ated blood cells from smoking and/or COPD patients and to 
cultured lung cells treated with tobacco smoke extract. In 
relation to this, the present study shows that the DNA dam-
age-specific histone, gamma-H2AX, is expressed in alveolar 
septal cells of some of the patients with marked COPD. The 
evidence of a DNA damage response supports the concept 
that cigarette smoke can activate cell senescence and/or cell 
death programs, leading to extensive lung injury and even-
tual alveolar destruction.2,8,34,35 Importantly,   abnormalities in 
survival and function of alveolar septal wall cells are known 
to contribute to COPD pathogenesis.2,8,34,35
Traditional concepts hold that oxidative DNA damage is 
a random event, but emerging data suggest that this may not 
be so; oxidative DNA damage may, in some   circumstances, 
be more prominent in the mitochondrial genome or in 
  functionally significant sequences of specific nuclear genes. 
For example, it is known that mtDNA is about 30-fold more 
sensitive to exogenous oxidants than nuclear DNA.12–14 
Indeed, in pulmonary and systemic vascular endothelial 
cells, exogenously applied oxidants cause prominent mtDNA 
damage at concentrations that fail to affect nuclear DNA 
integrity, even when highly sensitive oxidative damage 
detection methods are employed.13,14 However, more recent 
studies suggest that oxygen radicals used as second mes-
sengers in physiologic signaling might preferentially target 
nuclear DNA. In this regard, oxygen radicals generated dur-
ing hypoxic signaling in pulmonary artery smooth muscle and 
endothelial cells cause transient oxidative base modifications 
in promoter sequences, specifically in hypoxic responsive 
elements in hypoxia-inducible genes.17–19 The presence International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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of these hypoxia-induced oxidative base modifications in 
HRE sequences alters transcription factor binding, sequence 
flexibility, and reporter gene expression.36   Similarly, in 
MCF-7 cells, estrogen causes transient oxidative base dam-
age in estrogen-responsive promoter elements of the pS2 
and Bcl2 genes.16 In this case, the oxidant lesions seem to be 
caused by hydrogen peroxide generated by the DNA-bound 
histone demethylase, LSD1, during transcription-related 
histone demethylation. Finally, studies in cortical neurons 
from human subjects demonstrate that the age-dependent 
accumulation of persistent oxidative DNA damage in proxi-
mal promoter regions is associated with reduced expression 
of the affected genes.15 Collectively, these findings raise the 
intriguing possibility that a process of controlled oxidative 
DNA damage and repair could be linked to modulation of 
transcriptional activation.16,36
Against this background, the aim of the present study was 
to determine whether the previously reported oxidative DNA 
damage associated with COPD was randomly distributed 
between the mitochondrial and nuclear genomes or whether 
the damage displayed genome and/or sequence specificity. 
We found that abasic sites and strand breaks could detected 
in mtDNA from lung tissue from patients with severe COPD, 
which could reasonably be incriminated in at least several 
pathologic features of the disease. First, oxidative lesions in 
the mitochondrial genome have the potential to cause mtDNA 
mutations and to disrupt mtDNA transcription,31 which could 
contribute to the bioenergetic defects reported in COPD 
patients.37,38 Second, oxidative mtDNA damage is a proximate 
trigger for apoptosis in a spectrum of cultured cell types,39–42 
thus suggesting that oxidative damage to the mitochondrial 
genome in lung cells could initiate apoptotic processes linked 
to COPD development.43,44 Finally,   oxidative damage to the 
mitochondrial genome, probably by increasing mitochondrial 
oxidant production, also engenders nuclear hypermutability45 
which may be associated with the increased risk of lung cancer 
and with acquisition of somatic mutations believed to influ-
ence COPD pathogenesis and natural history.46
We focused our analysis of nuclear DNA damage on a 
limited number of genes selected because of their likely patho-
genic roles and altered expression in COPD.28–30 An inter-
esting finding reported herein was that out of 15 sequences 
examined in 5 different nuclear genes, Fpg-detectable base 
lesions were detected exclusively in the VEGF HRE in lungs 
from COPD patients. The unusual clustering of damage in the 
VEGF HRE raises intriguing questions about its biological 
significance, which is discussed below. However, the present 
observation that the VEGF promoter, among the handful of 
genes and sequences examined, is oxidatively damaged in 
COPD points to the need to survey a more extensive list of 
genes, who may have pathogenic roles and whose expression 
may be altered, in a larger cohort of COPD patients. In this 
manner, it might be possible to more clearly define the rela-
tion between the presence of promoter damage, alterations in 
transcript abundance, and other attributes of the pathogenesis 
and natural history of the disease.
As recently reviewed, VEGF plays a central role in main-
taining lung structure and function.20 Indeed, in rodent models, 
when the VEGF receptor type II is blocked pharmacologically 
or when VEGF signaling is disrupted using genetic strategies, 
lung cells undergo apoptotic and proliferative responses that 
culminate in emphysematous-like lesions.21–23 In humans with 
severe COPD, lung VEGF mRNA expression is reduced – a 
finding confirmed in the present report – and VEGF protein 
expression is attenuated.33,47–49 In light of these considerations, 
it is tempting to speculate that oxidative damage to the VEGF 
HRE could suppress VEGF mRNA expression in COPD by 
altering promoter conformation and impairing transcrip-
tion factor binding. Countering this idea are recent reports, 
noted above, suggesting that “controlled DNA damage and 
repair” in the VEGF HRE and key promoter sequences in 
other genes could be required for transcriptional activation, 
possibly by enabling short- and long-range changes in DNA 
topology.16,36,50 The finding that VEGF mRNA expression is 
decreased in COPD despite the presence of oxidative base 
modifications postulated to be important for transcriptional 
activation raises the notion that some aspect of the proposed 
process of controlled DNA damage and repair can be sub-
verted leading to persistent oxidative damage and an inability 
to activate gene   expression. Obviously, additional experiments 
will be required to test this concept.
In summary, the present study extends previous reports 
that oxidative DNA damage is present in lung cells from 
patients with COPD. The damage appears to be clustered in 
the   mitochondrial genome and in specific sequences of the 
promoter of the nuclear VEGF gene. The biological impor-
tance of this COPD-related, sequence-specific oxidative 
DNA damage remains to be determined, but it is reasonable 
to consider the prospect that such oxidative DNA damage 
could affect cell fate decisions and/or transcriptional regula-
tion of COPD-related genes and thereby contribute to disease 
pathogenesis.
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